Quick Answer
Zivo Bioscience, Inc. reported Revenue (ASC 606) of $157.2 thousand for fiscal year 2024.
Zivo Bioscience, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2024 | $157.2K | +468.6% |
| 2023 | $27.6K | — |
| 2022 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $65.6K | +108.3% | +22.9% |
| June 30, 2025 | $53.4K | — | — |
| March 31, 2025 | $0.00 | -100.0% | -100.0% |
| September 30, 2024 | $31.5K | +166.9% | — |
| June 30, 2024 | $0.00 | -100.0% | -100.0% |
| March 31, 2024 | $35.7K | — | +202.7% |
| September 30, 2023 | $11.8K | — | +191.4% |
| June 30, 2023 | $4.0K | — | — |
- Zivo Bioscience, Inc. showed an increase of +468.6% in Revenue (ASC 606) compared to the prior fiscal year.
- The most recent figure is from Zivo Bioscience, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 18, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: